Ritodrine
GENITO URINARY SYSTEM AND SEX HORMONES
Also known as: DU21220, lavopa, ritodrine HCl, ritodrine hydrochloride, yutopar
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Ritodrine is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 1991. DrugCentral lists 2 molecular targets, including ADRB2 and ADRB3. Recorded indications include Premature labor.
- Approval status: ofm (first approved 1991 by the FDA).
- Molecular targets: ADRB2 and ADRB3 (2 listed in DrugCentral).
- Indications: Premature labor.
- ATC code: G02CA01 (Sympathomimetics, labour repressants).
- Molecular formula: C17H21NO3; molecular weight 287.36 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Premature labor
Contraindications (15)
- Antepartum hemorrhage
- Chorioamnionitis
- Conduction disorder of the heart
- Dehydration
- Eclampsia in pregnancy
- Fetal death
- Gestational diabetes mellitus
- Hypertensive disorder
- Hypertensive urgency
- Hyperthyroidism
- Hypovolemia
- Migraine
- Mild pre-eclampsia
- Pulmonary hypertension
- Severe pre-eclampsia
Mechanism & targets
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Beta-2 adrenergic receptor | ADRB2 | agonist | EC50 7.62 |
| Beta-3 adrenergic receptor | ADRB3 | unknown | EC50 6.72 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1991-01-22 | FDA | — | HOSPIRA |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
G02CA01 | GENITO URINARY SYSTEM AND SEX HORMONES › OTHER GYNECOLOGICALS › OTHER GYNECOLOGICALS › Sympathomimetics, labour repressants |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Premature baby | 405.3 |
| Low birth weight baby | 366.0 |
| Foetal exposure during pregnancy | 309.6 |
| Exposure during pregnancy | 282.9 |
| Maternal exposure during pregnancy | 207.2 |
| Premature delivery | 185.6 |
Chemical structure
| Molecular formula | C17H21NO3 |
|---|---|
| Molecular weight | 287.36 g/mol |
| CAS number | 26652-09-5 |
| InChIKey | IOVGROKTTNBUGK-SJKOYZFVSA-N |
| PubChem CID | 33572 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Ritodrine used for?
DrugCentral lists the following indications for Ritodrine: Premature labor.
How does Ritodrine work?
Its molecular targets in DrugCentral include ADRB2 (agonist) and ADRB3.
When was Ritodrine first approved?
Ritodrine was first approved by the FDA in 1991.
What is the chemical formula of Ritodrine?
Ritodrine has the molecular formula C17H21NO3 and a molecular weight of 287.36 g/mol.
Browse: all drugs starting with R · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2390 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1367605 — compound record and bioactivity
- PubChem CID 33572 — chemical identifiers
- DrugBank DB00867 — drug record
- FDA UNII I0Q6O6740J — substance identity
- DailyMed: FDA labels for Ritodrine — current prescribing information (label search)
- UniProt P07550 (ADRB2) — target protein
- UniProt P13945 (ADRB3) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.